Presentation is loading. Please wait.

Presentation is loading. Please wait.

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study  Michael Davidson, MD, Michael Stevenson, RPh, PhD, Andrew Hsieh,

Published byAnn-Sofie Nilsson Modified over 5 years ago

Similar presentations

Presentation on theme: "The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study  Michael Davidson, MD, Michael Stevenson, RPh, PhD, Andrew Hsieh,"— Presentation transcript:

1 The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study 
Michael Davidson, MD, Michael Stevenson, RPh, PhD, Andrew Hsieh, PharmD, Zahid Ahmad, MD, Jeanine Roeters van Lennep, MD, PhD, Caroline Crowson, MEM, Joseph L. Witztum, MD  Journal of Clinical Lipidology  Volume 12, Issue 4, Pages e2 (July 2018) DOI: /j.jacl Copyright © 2018 National Lipid Association Terms and Conditions

2 Figure 1 Physical symptoms at their worst or most severe. For each symptom selected, patients indicated symptom severity and frequency. Severity was recorded on a Likert scale (range, 1–7; 1 = very mild, 7 = very severe). Frequency was recorded by selection from the following options: multiple times per day, daily, every other day, twice a week, once a week, or every other week. Sphere size in the chart is proportional to the percentage of patients who selected each symptom. Journal of Clinical Lipidology  , e2DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

3 Figure 2 Emotional symptoms at their worst or most severe. For each symptom selected, patients indicated symptom severity and frequency. Severity was recorded on a Likert scale (range, 1–7; 1 = very mild, 7 = very severe). Frequency was recorded by selection from the following options: multiple times per day, daily, every other day, twice a week, once a week, or every other week. Sphere size in the chart is proportional to the percentage of patients who selected each symptom. Journal of Clinical Lipidology  , e2DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

4 Figure 3 Cognitive symptoms at their worst or most severe. For each symptom selected, patients indicated symptom severity and frequency. Severity was recorded on a Likert scale (range, 1–7; 1 = very mild, 7 = very severe). Frequency was recorded by selection from the following options: multiple times per day, daily, every other day, twice a week, once a week, or every other week. Sphere size in the chart is proportional to the percentage of patients who selected each symptom. Journal of Clinical Lipidology  , e2DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

5 Figure 4 Number of acute pancreatitis episodes experienced by patients with FCS, who reported acute pancreatitis as a comorbidity. (A) Past 12 months. (B) Lifetime. Journal of Clinical Lipidology  , e2DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

6 Figure 5 Management strategies used by patients with FCS. Response percentages may total >100% because respondents may use >1 strategy. Journal of Clinical Lipidology  , e2DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

7 Figure 6 Overall interference of FCS with patients' life.
Journal of Clinical Lipidology  , e2DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

8 Figure 7 Impact of FCS on social relationships and activities.
Journal of Clinical Lipidology  , e2DOI: ( /j.jacl ) Copyright © 2018 National Lipid Association Terms and Conditions

Download ppt "The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study  Michael Davidson, MD, Michael Stevenson, RPh, PhD, Andrew Hsieh,"

Similar presentations

The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes 

The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes 
Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 

Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data  Steve E. Humphries, PhD, FRCP, Jackie Cooper,

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data  Steve E. Humphries, PhD, FRCP, Jackie Cooper,
Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
An assessment by the Statin Cognitive Safety Task Force: 2014 update

An assessment by the Statin Cognitive Safety Task Force: 2014 update
An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Muscle Safety Task Force: 2014 update
An assessment by the Statin Liver Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients  Eli O. Meltzer, MD, Judith.

Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients  Eli O. Meltzer, MD, Judith.
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents  James W. Baker, MD, Avner Reshef, MD, Dumitru Moldovan,

Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents  James W. Baker, MD, Avner Reshef, MD, Dumitru Moldovan,
The Burden of Polypharmacy in Patients Near the End of Life

The Burden of Polypharmacy in Patients Near the End of Life
Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,
A review of PCSK9 inhibition and its effects beyond LDL receptors

A review of PCSK9 inhibition and its effects beyond LDL receptors
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies  Christie.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies  Christie.

Similar presentations

Ads by Google